Healthcare expenditure and its predictors in a cohort of Australians living with sciatica

Alexander Chye; Chung Wei Christine Lin; Mark J. Hancock; Ian Harris; Jane Latimer; Christopher G. Maher; Andrew J. McLachlan; Stephanie Mathieson; Bart Koes; Richard O. Day; Laurent Billot; Stephen Jan; Blake Angell

doi:10.1007/s00586-020-06605-2

Healthcare expenditure and its predictors in a cohort of Australians living with sciatica

Alexander Chye^*, Chung Wei Christine Lin, Mark J. Hancock, Ian Harris, Jane Latimer, Christopher G. Maher, Andrew J. McLachlan, Stephanie Mathieson, Bart Koes, Richard O. Day, Laurent Billot, Stephen Jan, Blake Angell

^*Corresponding author for this work

General Practice

Research output: Contribution to journal › Article › Academic › peer-review

68 Downloads (Pure)

Abstract

Purpose: To estimate the healthcare resource utilisation of an Australian cohort of people with sciatica and explore individual-level factors associated with expenditure. Methods: Healthcare utilisation (services and medication) data from a randomised, double-blind, placebo-controlled trial of pregabalin in patients with sciatica (n = 185) were analysed to estimate healthcare expenditure of participants over 12 months. Associations between key baseline socio-economic, pain and quality of life characteristics and healthcare expenditure were examined using generalised linear imputation models. Results: On average, participants accessed AUD$1,134 of healthcare over the year, predominantly made up of $114 of medication and $914 of health services, which included $418 of physiotherapy services. Participants randomised to receive pregabalin incurred higher expenditure ($1,263 compared to $1,001 for placebo), which was largely driven by pregabalin ($158) and greater health services ($107). Healthcare expenditure was significantly higher for participants prescribed pregabalin, earning greater than $1,700 per week ($88,400 per year) and reporting poorer quality of life (physical and mental). Conclusion: Our results suggest inefficiency in the use of healthcare resources due to increased healthcare resource utilisation in people with sciatica treated with pregabalin, compared to placebo. Costs of treating sciatica varied based on individual quality of life and socio-economic characteristics.

Original language	English
Pages (from-to)	878-885
Number of pages	8
Journal	European Spine Journal
Volume	30
Issue number	4
Early online date	24 Sept 2020
DOIs	https://doi.org/10.1007/s00586-020-06605-2
Publication status	Published - Apr 2021

Bibliographical note

Funding Information:
AC, CL, SJ, JL, BK, RD, LB and BA declare no conflict of interest. CM received support from PHP International Pty Ltd for supply of heat wraps to a clinical trial; AM received support from GlaxoSmithKline Australia for a Ph.D. scholarship under his supervision. The authors confirm full control of all primary data and are happy for the journal to review if requested.

Funding Information:
This research was completed without funding. The original trial Pregabalin in Addition to Usual Care for Sciatica (PRECISE) was supported by a Grant (ID APP1042073) from the National Health and Medical Research Council of Australia with in-kind support from Pfizer Australia. Investigators of the PRECISE trial retained full autonomy over the design, conduct, analysis and reporting of the trial.

Publisher Copyright:
© 2020, Springer-Verlag GmbH Germany, part of Springer Nature.

Access to Document

10.1007/s00586-020-06605-2Licence: CC BY

Healthcare expenditure and its predictors in a cohort of Australians living with sciaticaFinal published version, 541 KBLicence: CC BY

Cite this

@article{de5532ceda1e4c86bfc2915ffcf051cd,

title = "Healthcare expenditure and its predictors in a cohort of Australians living with sciatica",

abstract = "Purpose: To estimate the healthcare resource utilisation of an Australian cohort of people with sciatica and explore individual-level factors associated with expenditure. Methods: Healthcare utilisation (services and medication) data from a randomised, double-blind, placebo-controlled trial of pregabalin in patients with sciatica (n = 185) were analysed to estimate healthcare expenditure of participants over 12 months. Associations between key baseline socio-economic, pain and quality of life characteristics and healthcare expenditure were examined using generalised linear imputation models. Results: On average, participants accessed AUD$1,134 of healthcare over the year, predominantly made up of $114 of medication and $914 of health services, which included $418 of physiotherapy services. Participants randomised to receive pregabalin incurred higher expenditure ($1,263 compared to $1,001 for placebo), which was largely driven by pregabalin ($158) and greater health services ($107). Healthcare expenditure was significantly higher for participants prescribed pregabalin, earning greater than $1,700 per week ($88,400 per year) and reporting poorer quality of life (physical and mental). Conclusion: Our results suggest inefficiency in the use of healthcare resources due to increased healthcare resource utilisation in people with sciatica treated with pregabalin, compared to placebo. Costs of treating sciatica varied based on individual quality of life and socio-economic characteristics.",

author = "Alexander Chye and Lin, {Chung Wei Christine} and Hancock, {Mark J.} and Ian Harris and Jane Latimer and Maher, {Christopher G.} and McLachlan, {Andrew J.} and Stephanie Mathieson and Bart Koes and Day, {Richard O.} and Laurent Billot and Stephen Jan and Blake Angell",

note = "Funding Information: AC, CL, SJ, JL, BK, RD, LB and BA declare no conflict of interest. CM received support from PHP International Pty Ltd for supply of heat wraps to a clinical trial; AM received support from GlaxoSmithKline Australia for a Ph.D. scholarship under his supervision. The authors confirm full control of all primary data and are happy for the journal to review if requested. Funding Information: This research was completed without funding. The original trial Pregabalin in Addition to Usual Care for Sciatica (PRECISE) was supported by a Grant (ID APP1042073) from the National Health and Medical Research Council of Australia with in-kind support from Pfizer Australia. Investigators of the PRECISE trial retained full autonomy over the design, conduct, analysis and reporting of the trial. Publisher Copyright: {\textcopyright} 2020, Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2021",

month = apr,

doi = "10.1007/s00586-020-06605-2",

language = "English",

volume = "30",

pages = "878--885",

journal = "European Spine Journal",

issn = "0940-6719",

publisher = "Springer-Verlag",

number = "4",

}

TY - JOUR

T1 - Healthcare expenditure and its predictors in a cohort of Australians living with sciatica

AU - Chye, Alexander

AU - Lin, Chung Wei Christine

AU - Hancock, Mark J.

AU - Harris, Ian

AU - Latimer, Jane

AU - Maher, Christopher G.

AU - McLachlan, Andrew J.

AU - Mathieson, Stephanie

AU - Koes, Bart

AU - Day, Richard O.

AU - Billot, Laurent

AU - Jan, Stephen

AU - Angell, Blake

N1 - Funding Information: AC, CL, SJ, JL, BK, RD, LB and BA declare no conflict of interest. CM received support from PHP International Pty Ltd for supply of heat wraps to a clinical trial; AM received support from GlaxoSmithKline Australia for a Ph.D. scholarship under his supervision. The authors confirm full control of all primary data and are happy for the journal to review if requested. Funding Information: This research was completed without funding. The original trial Pregabalin in Addition to Usual Care for Sciatica (PRECISE) was supported by a Grant (ID APP1042073) from the National Health and Medical Research Council of Australia with in-kind support from Pfizer Australia. Investigators of the PRECISE trial retained full autonomy over the design, conduct, analysis and reporting of the trial. Publisher Copyright: © 2020, Springer-Verlag GmbH Germany, part of Springer Nature.

PY - 2021/4

Y1 - 2021/4

N2 - Purpose: To estimate the healthcare resource utilisation of an Australian cohort of people with sciatica and explore individual-level factors associated with expenditure. Methods: Healthcare utilisation (services and medication) data from a randomised, double-blind, placebo-controlled trial of pregabalin in patients with sciatica (n = 185) were analysed to estimate healthcare expenditure of participants over 12 months. Associations between key baseline socio-economic, pain and quality of life characteristics and healthcare expenditure were examined using generalised linear imputation models. Results: On average, participants accessed AUD$1,134 of healthcare over the year, predominantly made up of $114 of medication and $914 of health services, which included $418 of physiotherapy services. Participants randomised to receive pregabalin incurred higher expenditure ($1,263 compared to $1,001 for placebo), which was largely driven by pregabalin ($158) and greater health services ($107). Healthcare expenditure was significantly higher for participants prescribed pregabalin, earning greater than $1,700 per week ($88,400 per year) and reporting poorer quality of life (physical and mental). Conclusion: Our results suggest inefficiency in the use of healthcare resources due to increased healthcare resource utilisation in people with sciatica treated with pregabalin, compared to placebo. Costs of treating sciatica varied based on individual quality of life and socio-economic characteristics.

AB - Purpose: To estimate the healthcare resource utilisation of an Australian cohort of people with sciatica and explore individual-level factors associated with expenditure. Methods: Healthcare utilisation (services and medication) data from a randomised, double-blind, placebo-controlled trial of pregabalin in patients with sciatica (n = 185) were analysed to estimate healthcare expenditure of participants over 12 months. Associations between key baseline socio-economic, pain and quality of life characteristics and healthcare expenditure were examined using generalised linear imputation models. Results: On average, participants accessed AUD$1,134 of healthcare over the year, predominantly made up of $114 of medication and $914 of health services, which included $418 of physiotherapy services. Participants randomised to receive pregabalin incurred higher expenditure ($1,263 compared to $1,001 for placebo), which was largely driven by pregabalin ($158) and greater health services ($107). Healthcare expenditure was significantly higher for participants prescribed pregabalin, earning greater than $1,700 per week ($88,400 per year) and reporting poorer quality of life (physical and mental). Conclusion: Our results suggest inefficiency in the use of healthcare resources due to increased healthcare resource utilisation in people with sciatica treated with pregabalin, compared to placebo. Costs of treating sciatica varied based on individual quality of life and socio-economic characteristics.

UR - http://www.scopus.com/inward/record.url?scp=85091428591&partnerID=8YFLogxK

U2 - 10.1007/s00586-020-06605-2

DO - 10.1007/s00586-020-06605-2

M3 - Article

C2 - 32970236

AN - SCOPUS:85091428591

SN - 0940-6719

VL - 30

SP - 878

EP - 885

JO - European Spine Journal

JF - European Spine Journal

IS - 4

ER -

Healthcare expenditure and its predictors in a cohort of Australians living with sciatica

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this